Rapid Micro Biosystems, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert G. Spignesi Jr.
- Full Time Employees
- 171
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 25 Hartwell Avenue Lexington MA United States of America 02421
- IPO Date
- Jul 15, 2021
- CIK
- 0001380106
- Website
- rapidmicrobio.com
- Similar Companies
- Business
- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) is a life sciences technology company providing mission-critical automation solutions for microbial quality control testing in pharmaceutical manufacturing; its flagship Growth Direct platform includes automated systems, proprietary consumables, lab information management system connection software such as RMBNucleus Mold Alarm, and validation and customer support services for applications including environmental monitoring, water testing, bioburden testing, sterility release testing, and mold detection in biologics, vaccines, cell and gene therapies, sterile injectables, medical devices, personal care products, cosmetics, and food and beverage sectors. The company operates globally in the United States, Germany, Switzerland, Japan, the Netherlands, North America, Europe, and Asia Pacific from its headquarters in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts; founded in 2006 and formerly known as Genomic Profiling Systems, Inc., it serves top pharmaceutical companies to accelerate results, enhance data integrity, reduce errors, and improve compliance. Recent developments include a five-year global co-exclusive distribution and collaboration agreement with MilliporeSigma (Merck KGaA's Life Science business) announced in February 2025 for Growth Direct systems and consumables, featuring minimum system purchase commitments in the first two years and joint efforts on cost savings and innovation; a $45 million growth capital commitment from Trinity Capital Inc. in 2025 with $20 million initially funded to support platform expansion, manufacturing efficiencies, and gross margin improvements; raised 2025 revenue guidance to at least $33 million following record Q3 recurring revenue and a major multi-system order from a top-20 global biopharma across multiple regions.
Company News
Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID)
Many Bright Ideas Technologies (OTCMKTS:MBGNF) versus Rapid Micro Biosystems (NASDAQ:RPID) Head to Head Contrast
Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?
Rapid Micro Biosystems, Inc. (RPID) Q2 2026 Earnings Call Transcript
Rapid Micro Biosystems Q2 Earnings Call Highlights
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates
Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
Rapid Micro Biosystems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering
Rapid Micro Biosystems Q1 Earnings Call Highlights
Rapid Micro Biosystems, Inc. (RPID) Q1 2026 Earnings Call Transcript
Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates
Rapid Micro Biosystems Reports First Quarter 2026 Financial Results
Rapid Micro Biosystems to Announce First Quarter 2026 Financial Results on May 13, 2026
What Makes Rapid Micro Biosystems (RPID) a New Buy Stock
Rapid Micro Biosystems Q4 Earnings Call Highlights
Rapid Micro Biosystems: Big Pharma Adoption Driving Growth